The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comprehensive molecular profiling of metastatic melanoma to predict response to monotherapy and combination immunotherapy.
 
Ines Esteves Domingues Pires Da Silva
No Relationships to Disclose
 
Alexander M. Menzies
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Novartis; Pierre Fabre; Roche
 
Felicity Newell
No Relationships to Disclose
 
James S. Wilmott
No Relationships to Disclose
 
Matteo S. Carlino
Honoraria - Bristol-Myers Squibb; MSD; Novartis
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre
 
Peter M. Ferguson
No Relationships to Disclose
 
Jarem Edwards
No Relationships to Disclose
 
Andrew Spillane
No Relationships to Disclose
 
Kerwin Shannon
No Relationships to Disclose
 
Robyn Saw
Honoraria - Merck Sharp & Dohme; Novartis
Consulting or Advisory Role - Merck Sharp & Dohme; Novartis
 
John F. Thompson
Honoraria - Bristol-Myers Squibb; GlaxoSmithKline; MSD Australia; Provectus
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; MSD Australia; Provectus
 
Helen Rizos
No Relationships to Disclose
 
Graham J. Mann
No Relationships to Disclose
 
Peter Johansson
No Relationships to Disclose
 
Nicholas Hayward
No Relationships to Disclose
 
Richard A. Scolyer
No Relationships to Disclose
 
Nic Waddell
No Relationships to Disclose
 
Georgina V. Long
Honoraria - Bristol-Myers Squibb; Merck; Pierre Fabre
Consulting or Advisory Role - Aduro Biotech; Array BioPharma; Bristol-Myers Squibb; Incyte; MERCK; Novartis; OncoSec; Pierre Fabre
Research Funding - BMS Brazil (Inst); Merck (Inst)